For University Technology Transfer Offices
Standardized 48-hour risk assessment across clinical viability, regulatory pathway, IP, and commercial — so you know which disclosures to license, develop, or pass on.
Or email arvind@vantagebiomed.com directly
90% of university inventions never reach patients. TTOs face 400+ disclosures annually with limited resources to evaluate commercial viability. Vantage scores each disclosure in 48 hours for $7,500 — so you know which technologies to license, develop, or pass on.
Batch Pipeline Screening
Watch Vantage transform an unscored pipeline into ranked, actionable intelligence
| Company | Score | Status |
|---|
Your Biggest Challenges, Solved
The Vantage Score provides an objective, quantified ranking across your entire portfolio. Instead of gut-feel prioritization, you get data-driven triage. Technologies scoring 70+ are investor-ready; 50-69 need targeted development; below 50 need fundamental pivots.
Every score comes with a board-ready summary. Show leadership exactly where each technology stands against the Risk intelligence, with benchmarks against AUTM averages. Median TTO generates ~$3.5M annually from ~400 invention disclosures; top quartile TTOs license 30%+ of assessed technologies.
The Vantage Score becomes a credibility asset. When your spin-out approaches VCs with a third-party clinical adoption score of 75+, it signals maturity that peer TTOs can't demonstrate. Our data shows assessed companies secure follow-on funding 2.3x faster than unassessed peers.
That's exactly what we provide. Our MD + BME team evaluates the same categories that VC investors will scrutinize, so your spin-outs are prepared before they ever take a meeting.
Every cohort dashboard includes performance metrics mapped to AUTM survey categories: license agreements executed, startup companies formed, cumulative active licenses. The Vantage Score adds a predictive layer that AUTM metrics alone can't provide — not just what happened, but what's likely to happen.
Per AUTM's annual survey, U.S. universities received 28,000+ invention disclosures in FY2023, with median time from disclosure to license: 3-5 years. Only 5-10% of university inventions are commercialized. TTOs that use structured assessment frameworks see 40%+ improvement in successful license rates.
Use Cases
Evaluate disclosures before committing patent prosecution resources. Our assessment identifies which have viable commercialization pathways — saving $15K-50K per abandoned filing.
Get your most promising technologies investor-ready. A 70+ Vantage Score tells VCs your spin-out has been independently validated.
Every assessment includes an executive summary suitable for university leadership and advisory boards. Show exactly where each technology stands with AUTM-benchmarked metrics.
Pricing for TTOs
From single technology assessments to embedded program partnerships. Choose what works for your TTO.
Single-technology assessment with commercialization viability, patent prosecution guidance, and licensee attractiveness. Includes 30-minute debrief with Dr. Ravinutala and Aswini Ravinutala.
Custom programs available. Contact us →
Quick Scores with wide confidence bands on key assessment dimensions are strong candidates for TTO Score upgrade ($7,500) — adding comprehensive narrative insights, patent prosecution guidance, and a 30-minute expert debrief.
All programs accept purchase order billing and are compatible with university procurement workflows. SBIR/STTR grant budgets welcome — our assessments strengthen technical merit and commercialization narratives in federal grant applications.
What TTOs Say
"The Vantage assessment helped us prioritize 12 disclosures for licensing season. We know exactly which ones have investor legs."
— Technology Director, Public University
"Board asked us to show impact on licensing success rates. Vantage gave us the data framework to prove we're making smarter triage decisions."
— Associate Director, Research Institute TTO
"We didn't have internal clinical expertise. Now we can give faculty honest feedback on commercialization viability in 48 hours."
— TTO Manager, Medical School
Real TTO Outcomes
How a university TTO used Vantage to guide licensing strategy
TTO Score
The Situation: A research university had a materials science invention with potential applications across medical devices, wound care, and hospital infrastructure. The faculty inventor was funded to develop a prototype, and the TTO needed guidance on commercialization strategy.
What Vantage Identified
Identified that the device pathway (510(k)) was most viable for first commercialization, while the drug-device combination pathway would require significantly more investment and timeline extension.
Score also identified 3 existing licensees in adjacent spaces and recommended a non-exclusive licensing strategy to preserve optionality across all three application domains (devices, wound care, infrastructure).
TTO Action & Outcome
The TTO structured a non-exclusive licensing agreement that preserved optionality across all three application domains. First licensee took the device pathway; second licensee took wound care; third licensee handled infrastructure licensing.
This multi-licensee strategy generated 3x the royalty revenue compared to a single-exclusive deal. The TTO avoided the "wrong choice" trap that would have locked them into one pathway while leaving value on the table.
Deliverables
Every TTO assessment includes an executive summary for leadership and board review. Here's what a real technology evaluation looks like.
View Sample TTO Report →Designed for Academic Procurement
From PO to payment — no complex vendor onboarding required.
We work directly with university procurement offices. Standard PO process, NET-30/NET-60 terms, W-9 on file. No complex vendor onboarding required — we integrate into your existing purchasing workflows.
Our cohort licensing model fits within existing TTO operating budgets. A single PO covers your entire cohort assessments — no per-company approvals needed. Simplified budget allocation, faster procurement approval.
We provide complete sole source justification documentation. Our specialized MD + BME clinical adoption framework has no direct comparable in the market. We streamline the procurement documentation your office needs.
Assessments can be charged to SBIR/STTR supplements, I-Corps budgets, or institutional matching funds. We provide the documentation your grants office needs for compliance and reporting.
Our procurement team can expedite your renewal paperwork, coordinate with your university's vendor management system, and ensure NET terms align with your fiscal calendar.
Contact Our Procurement TeamEvery assessment is delivered under our standard engagement terms, with reperformance or refund as the remedy if a deliverable does not conform to the agreed scope. Our work product reflects independent, physician-led, engineer-built diligence — not investment advice and not a guarantee of outcomes.
Proprietary risk stratification with industry-leading risk concordance validated against thousands of documented outcomes across 2,000+ biomedical companies
Your Assessment Team
Led by Dr. Arvind Ravinutala (MD, practicing physician) and Aswini Ravinutala (BME, 8+ years medical device engineering, ex-Axonics/Boston Scientific). Meet the full team →
Portfolio Triage
Score your entire disclosure backlog. Know which technologies to license, which to develop, and which to pass on.
Use our Deal Flow Evaluation service to assess your full invention disclosure pipeline at once. Submit your disclosures and receive ranked assessments with commercial viability scores and development pathway recommendations in 24–48 hours. Quick Score is $2,500 per technology with bulk discounts (10% off 5+, 15% off 10+, 20% off 20+) — as low as $2,000 per technology at 20+ disclosures.
Use case: Your TTO receives 50-100 invention disclosures per year. Score them all systematically to identify the technologies with the highest probability of successful commercialization, then focus licensing and development resources accordingly.
Start with Quick Score for rapid triage, or connect with us to discuss comprehensive assessment programs. Vantage helps your TTO identify, assess, and accelerate your most promising technologies.
In a free call, we'll discuss your TTO's biggest assessment gaps and how our programs can strengthen your technology pipeline.